Jeremy P Feldman MD

Pulmonology•Bend, OR

Critical Care Medicine, Interventional Pulmonology, Pleural Disease

Founder JPF Advisors Co-Founder Inspire Pulmonary Media

Join to View Full Profile

1501 NE Medical Center DrBend, OR 97701
Phone+1 541-382-4900
Fax+1 541-706-5273

Summary

I have dedicated the past 20 years to pulmonary vascular disease and advanced lung disease.

I have created educational websites for pulmonary hypertension (pulmonaryhypertensionRN.com) and pulmonary fibrosis (pulmonaryfibrosisMD.com)

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2004
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
University of California San Diego School of MedicineClass of 1998

Certifications & Licensure

AZ State Medical License 2004 - 2027
CA State Medical License 2001 - 2026
OR State Medical License 2021 - 2025
MA State Medical License 2000 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
Completed
Phase 2
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies Start of enrollment: 2010 Dec 01
Completed
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
Completed
Phase 3
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Start of enrollment: 2013 Sep 11
Completed
Phase 3
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Start of enrollment: 2014 May 31
Completed
Phase 2
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Pulmonary Hypertension Association Registry Start of enrollment: 2015 Oct 01
Recruiting
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2) Start of enrollment: 2021 Mar 15
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension inMutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Pla...
David Montani, Vallerie V McLaughlin, J Simon R Gibbs, Mardi Gomberg-Maitland, Marius M Hoeper
American Journal of Respiratory and Critical Care Medicine. 2025-03-04
2 citations
IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.
Hunter Gillies, Murali M Chakinala, Benjamin T Dake, Jeremy P Feldman, Marius M Hoeper
Pulmonary Circulation. 2024-01-01
Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypert...
Hilary M DuBrock, Charles D Burger, Sonja D Bartolome, Jeremy P Feldman, David D Ivy
Pulmonary Circulation. 2022-10-01

Press Mentions

Phase 3 INOpulse Trial Enrolls First Patient at Risk of PF-Associated PHDecember 4th, 2020
First Patient Enrolled in Phase 3 REBUILD Trial of INOpulseDecember 4th, 2020
New Pulmonary Hypertension Association Accreditation Program and Registry Giving New Understanding to Specialists Caring for People Living with Pulmonary HypertensionFebruary 3rd, 2017

External Links

Pulmonary Hypertensionhttp://www.pulmonaryhypertensionRN.com
Pulmonary Fibrosishttp://www.pulmonaryfibrosisMD.com
Consultinghttp://JPFAdvisors.com